$SKYE
Skye Bioscience, Inc.

2024 Q3 Form 10-Q Financial Statement

#000151655124000070 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.639M $4.327M
YoY Change 107.1% 258.65%
% of Gross Profit
Research & Development $4.883M $4.079M
YoY Change 289.22% 128.06%
% of Gross Profit
Depreciation & Amortization $47.52K $29.79K
YoY Change 58.4% -12.18%
% of Gross Profit
Operating Expenses $4.969M $8.406M
YoY Change -79.89% 195.66%
Operating Profit -$4.969M -$8.406M
YoY Change -79.89% 195.66%
Interest Expense $997.7K $510.8K
YoY Change 267.73% 174.01%
% of Operating Profit
Other Income/Expense, Net $1.070M $510.8K
YoY Change -545.91% -292.84%
Pretax Income -$3.898M -$7.895M
YoY Change -84.37% 154.02%
Income Tax $0.00 $8.071K
% Of Pretax Income
Net Earnings -$3.898M -$7.903M
YoY Change -84.37% 153.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.20
Diluted Earnings Per Share -$0.10 -$0.20
COMMON SHARES
Basic Shares Outstanding 30.34M shares 28.07M shares
Diluted Shares Outstanding 38.82M shares 38.67M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.63M $76.28M
YoY Change 1257.29% 9020.53%
Cash & Equivalents $67.41M $74.12M
Short-Term Investments
Other Short-Term Assets $2.651M $2.707M
YoY Change 205.42% 154.42%
Inventory
Prepaid Expenses $664.6K $1.096M
Receivables
Other Receivables
Total Short-Term Assets $79.81M $87.00M
YoY Change 422.09% 4496.88%
LONG-TERM ASSETS
Property, Plant & Equipment $1.517M $45.77K
YoY Change 2643.51% -28.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.31K $8.309K
YoY Change 216.64% 0.0%
Total Long-Term Assets $1.727M $257.1K
YoY Change 442.98% -25.11%
TOTAL ASSETS
Total Short-Term Assets $79.81M $87.00M
Total Long-Term Assets $1.727M $257.1K
Total Assets $81.54M $87.26M
YoY Change 422.52% 3802.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $780.0K $1.079M
YoY Change -52.19% -30.42%
Accrued Expenses $2.641M $2.140M
YoY Change 106.36% 30.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $4.860M
YoY Change -100.0%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $5.624M $14.32M
YoY Change -59.0% 45.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $108.1K $129.9K
YoY Change -43.13% -37.72%
Total Long-Term Liabilities $108.1K $129.9K
YoY Change -43.13% -37.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.624M $14.32M
Total Long-Term Liabilities $108.1K $129.9K
Total Liabilities $5.732M $14.45M
YoY Change -58.79% 44.16%
SHAREHOLDERS EQUITY
Retained Earnings -$121.2M -$117.3M
YoY Change 21.25% 56.37%
Common Stock $197.0M $190.1M
YoY Change 93.79% 182.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $75.80M $72.81M
YoY Change
Total Liabilities & Shareholders Equity $81.54M $87.26M
YoY Change 422.52% 3802.67%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.898M -$7.903M
YoY Change -84.37% 153.99%
Depreciation, Depletion And Amortization $47.52K $29.79K
YoY Change 58.4% -12.18%
Cash From Operating Activities -$5.263M -$7.094M
YoY Change 29.62% 256.13%
INVESTING ACTIVITIES
Capital Expenditures $1.518M $32.46K
YoY Change 15083.6%
Acquisitions
YoY Change
Other Investing Activities $72.84K $0.00
YoY Change -93.26%
Cash From Investing Activities -$1.446M -$32.46K
YoY Change -235.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -2.096M
YoY Change -100.0% 1598.45%
NET CHANGE
Cash From Operating Activities -5.263M -7.094M
Cash From Investing Activities -1.446M -32.46K
Cash From Financing Activities 0.000 -2.096M
Net Change In Cash -6.708M -9.222M
YoY Change -149.14% 335.98%
FREE CASH FLOW
Cash From Operating Activities -$5.263M -$7.094M
Capital Expenditures $1.518M $32.46K
Free Cash Flow -$6.781M -$7.126M
YoY Change 66.61% 257.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
skye Wind Down Costs
WindDownCosts
470181 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3111500 usd
us-gaap Net Income Loss
NetIncomeLoss
-12922347 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-691073 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1249107 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83201056 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
558034 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4591 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
558034 usd
skye Financing Of Insurance Premium
FinancingOfInsurancePremium
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2980521 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5167520 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4780569 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102871 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3111500 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-7789198 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segments
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segments
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.004
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12349243 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12349243 shares
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4326820 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1206405 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8532620 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3121683 usd
CY2024Q2 skye Gain Loss From Estimated Legal Contingency
GainLossFromEstimatedLegalContingency
0 usd
CY2023Q2 skye Gain Loss From Estimated Legal Contingency
GainLossFromEstimatedLegalContingency
151842 usd
skye Gain Loss From Estimated Legal Contingency
GainLossFromEstimatedLegalContingency
0 usd
skye Gain Loss From Estimated Legal Contingency
GainLossFromEstimatedLegalContingency
151842 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8405571 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2842997 usd
us-gaap Operating Expenses
OperatingExpenses
14557821 usd
us-gaap Operating Expenses
OperatingExpenses
5943155 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8405571 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2842997 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14557821 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5943155 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
450052 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
186429 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
886988 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
204828 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
961237 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8598 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1388791 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
33112 usd
CY2024Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1145141 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-307086 usd
CY2024Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
CY2023Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
1383285 usd
CY2024Q2 skye Wind Down Costs
WindDownCosts
0 usd
CY2023Q2 skye Wind Down Costs
WindDownCosts
87072 usd
skye Wind Down Costs
WindDownCosts
0 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-359 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1399 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
510826 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-264903 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1645545 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2332265 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7894745 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3107900 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12912276 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8275420 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8071 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10071 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7902816 usd
us-gaap Net Income Loss
NetIncomeLoss
-8279020 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38669330 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3886198 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33334616 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3827216 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38669330 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3886198 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33334616 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3827216 shares
us-gaap Net Income Loss
NetIncomeLoss
-12922347 usd
us-gaap Net Income Loss
NetIncomeLoss
-8279020 usd
us-gaap Depreciation
Depreciation
57350 usd
us-gaap Depreciation
Depreciation
67091 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4306653 usd
us-gaap Share Based Compensation
ShareBasedCompensation
234450 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
487527 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 usd
skye Vendor Deposit Write Down
VendorDepositWriteDown
246000 usd
skye Vendor Deposit Write Down
VendorDepositWriteDown
0 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
30329 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1145141 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-307086 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-10794 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
1383285 usd
skye Accrued Interest Conversion Expense
AccruedInterestConversionExpense
0 usd
skye Accrued Interest Conversion Expense
AccruedInterestConversionExpense
15952 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
45350 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
901780 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-714152 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1833439 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
432975 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-76292 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-118487 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-16600 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-331808 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
256195 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-34196 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-45794 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
186243 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-28995 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
0 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-94078 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11801659 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6052759 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1145141 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
5532266 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35644 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1860 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1109497 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5530406 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6434447 usd
skye Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
83556563 usd
skye Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
168720 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83556563 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-168720 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72864401 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10336655 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74120854 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553443 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
9080202 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83201056 usd
skye Common Stock Warrant Exercises
CommonStockWarrantExercises
0 usd
skye Common Stock Warrant Exercises
CommonStockWarrantExercises
282905 usd
skye Conversion Of Multi Draw Credit Agreement
ConversionOfMultiDrawCreditAgreement
0 usd
skye Conversion Of Multi Draw Credit Agreement
ConversionOfMultiDrawCreditAgreement
1565470 usd
skye Conversion Of Accrued Interest Due To Related Party
ConversionOfAccruedInterestDueToRelatedParty
0 usd
skye Conversion Of Accrued Interest Due To Related Party
ConversionOfAccruedInterestDueToRelatedParty
31766 usd
skye Financing Of Insurance Premium
FinancingOfInsurancePremium
203884 usd
skye Release Of Share Liability To Additional Paid In Capital
ReleaseOfShareLiabilityToAdditionalPaidInCapital
0 usd
skye Release Of Share Liability To Additional Paid In Capital
ReleaseOfShareLiabilityToAdditionalPaidInCapital
241134 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2131818 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2478179 usd
CY2024Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
6434447 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83556563 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5019531 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
78883393 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1828474 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7902816 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
72809051 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3008054 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131579 usd
CY2023Q1 skye Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
282905 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1145141 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-307086 usd
CY2024Q2 skye Prepaid Clinical Expenses
PrepaidClinicalExpenses
74866 usd
CY2023Q4 skye Prepaid Clinical Expenses
PrepaidClinicalExpenses
61352 usd
CY2024Q2 skye Prepaid Financial Advisory Service Agreement
PrepaidFinancialAdvisoryServiceAgreement
568340 usd
CY2023Q4 skye Prepaid Financial Advisory Service Agreement
PrepaidFinancialAdvisoryServiceAgreement
0 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
452833 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
132907 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1096039 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
194259 usd
CY2024Q2 skye Tax Rebate Current
TaxRebateCurrent
548646 usd
CY2023Q4 skye Tax Rebate Current
TaxRebateCurrent
540604 usd
CY2024Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
2158702 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
403439 usd
CY2024Q2 skye Excise Tax Bonds Current
ExciseTaxBondsCurrent
0 usd
CY2023Q4 skye Excise Tax Bonds Current
ExciseTaxBondsCurrent
125784 usd
CY2024Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
20 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
32458 usd
CY2024Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
0 usd
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
17644 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2707368 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1119929 usd
CY2024Q2 skye Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
750049 usd
CY2023Q4 skye Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
467784 usd
CY2024Q2 skye Legal Professional Fee Accrual
LegalProfessionalFeeAccrual
233282 usd
CY2023Q4 skye Legal Professional Fee Accrual
LegalProfessionalFeeAccrual
258213 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
180897 usd
CY2024Q2 skye Travel And Entertainment Expenses Accrual
TravelAndEntertainmentExpensesAccrual
25479 usd
CY2023Q4 skye Travel And Entertainment Expenses Accrual
TravelAndEntertainmentExpensesAccrual
0 usd
CY2024Q2 skye Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
23756 usd
CY2023Q4 skye Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
0 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
141100 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
69468 usd
CY2024Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
11129 usd
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
22190 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1184795 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
998552 usd
CY2024Q2 skye Class Of Warrant Or Right Warrants Vested And Outstanding
ClassOfWarrantOrRightWarrantsVestedAndOutstanding
13251679 shares
CY2024Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
2761474 usd
CY2024Q2 skye Interest Expense Related Party Stated Rate
InterestExpenseRelatedPartyStatedRate
124658 usd
CY2023Q2 skye Interest Expense Related Party Stated Rate
InterestExpenseRelatedPartyStatedRate
0 usd
skye Interest Expense Related Party Stated Rate
InterestExpenseRelatedPartyStatedRate
249315 usd
skye Interest Expense Related Party Stated Rate
InterestExpenseRelatedPartyStatedRate
15952 usd
CY2024Q2 skye Legal Fees Interest Expense
LegalFeesInterestExpense
75189 usd
CY2023Q2 skye Legal Fees Interest Expense
LegalFeesInterestExpense
182171 usd
skye Legal Fees Interest Expense
LegalFeesInterestExpense
150146 usd
skye Legal Fees Interest Expense
LegalFeesInterestExpense
182171 usd
CY2024Q2 us-gaap Interest Expense Other
InterestExpenseOther
0 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
4258 usd
us-gaap Interest Expense Other
InterestExpenseOther
0 usd
us-gaap Interest Expense Other
InterestExpenseOther
6705 usd
CY2024Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
243331 usd
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
474133 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2024Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6874 usd
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
13394 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
450052 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
186429 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
886988 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
204828 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5000 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1828469 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
102871 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4306653 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234450 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11848634 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M1D
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7902816 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7902816 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3111500 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3111500 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12922347 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12922347 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8279020 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8279020 usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38669330 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38669330 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3886198 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3886198 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33334616 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33334616 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3827216 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3827216 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
CY2024Q2 skye Legal Fees Interest Expense
LegalFeesInterestExpense
75189 usd
skye Legal Fees Interest Expense
LegalFeesInterestExpense
150146 usd
CY2024Q2 skye Loss Contingency Net Cash Received To Cover Legal Expenses
LossContingencyNetCashReceivedToCoverLegalExpenses
5000000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001516551-24-000070-index-headers.html Edgar Link pending
0001516551-24-000070-index.html Edgar Link pending
0001516551-24-000070.txt Edgar Link pending
0001516551-24-000070-xbrl.zip Edgar Link pending
a101_skyebio-inducementequ.htm Edgar Link pending
a102_skyebioscience-induce.htm Edgar Link pending
a103_skyebio-formofrestric.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skye-20240630.htm Edgar Link pending
skye-20240630.xsd Edgar Link pending
skye-20240630xex311.htm Edgar Link pending
skye-20240630xex312.htm Edgar Link pending
skye-20240630xex321.htm Edgar Link pending
skye-20240630xex322.htm Edgar Link pending
skye-20240630_cal.xml Edgar Link unprocessable
skye-20240630_def.xml Edgar Link unprocessable
skye-20240630_lab.xml Edgar Link unprocessable
skye-20240630_pre.xml Edgar Link unprocessable
skye-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable